gastric juice protein raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
== Awards == JWD received the Thailand Sustainability Investment (THSI) award in 2018, 2019, 2020 and 2021 The award is granted to the listed companies with excellent performance in corporate governance and social responsibility.
More than 650,000 Americans have died of drug overdoses since the opioid epidemic began. The deaths attributable to opioid overdose increased from 16 deaths to 595 deaths per 100,000 population in the US.
=== Intramural and extramural research === In 2019, the NIH devoted 10% of its funding to research within its own facilities (intramural research), and gave >80% of its funding in research grants to extramural (outside) researchers. Of this extramural funding, a certain percentage (2.8% in 2014) must be granted to small businesses under the SBIR/STTR program. As of 2011, the extramural funding consisted of about 50,000 grants to more than 325,000 researchers at more than 3000 institutions. By 2018, this rate of granting remained reasonably steady, at 47,000 grants to 2,700 organizations. In FY 2010, the NIH spent US$10.7bn (not including temporary funding from the American Recovery and Reinvestment Act of 2009) on clinical research, US$7.4bn on genetics-related research, US$6.0bn on prevention research, US$5.8bn on cancer, and US$5.7bn on biotechnology.
Researchers are trying to develop a technique that can fulfil what current techniques are lacking: high throughput, higher sensitivity for metabolites that have a lower abundance or that have low ionization efficiencies, good replicability and that allow quantification of metabolites.
Sources: en.wikipedia.org
== External links == Molds and Moisture – Environmental Protection Agency (EPA) http://www2.lib.udel.edu/Preservation/mold.htm http://preserve.harvard.edu/guidelines/_mold.contamination.pdf http://www.loc.gov/preserv/emerg/dry.html
== Ownership == The Nobel Institute places no restrictions on the ownership of the medal and the accompanying diploma and prize money once it has been awarded to the recipient. If the recipient chooses not to keep them, they may be sold, donated, or given away. The dedicatee cannot be changed and the prizes cannot be revoked.
'The Omega Glory' is not, however, a counter-hegemonic episode. In fact, the episode not only reveals an unwillingness to be critical of the hegemony of racist representations, but also systematically participates in the stereotyping of Asians. As the story progresses, the Yangs are constructed as noble savages; their cause to annihilate the Comms is established as justified. The Comms, on the other hand, are constructed as brutal and oppressive; their drive to suppress the Yangs is established as totalitarian. This more hegemonic articulation of race is made evident when Kirk and Spock realize the extent to which the Yangs and Comms parallel Earth's civilizations. In this light, the Yangs are no longer savages, but noble warriors fighting for a just and honorable cause. They want to regain the land they lost in a war with the Asiatics. Allan W. Austin, Professor of History at Misericordia University, writes that this episode
With Esther Snyder's death in 2006 at the age of 86, the presidency passed to Mark Taylor, former vice president of operations. Taylor became the company's fifth president and first non-family member to hold the position, although he did have ties to the family. The company's current heiress is Lynsi Snyder, daughter of Guy and only grandchild of Esther and Harry Snyder. Snyder, who was 23 years old and known as Lynsi Martinez at her grandmother's death, owns the company through a trust. She gained control of 50% of the company in 2012 when she turned 30, and nearly full control at 35 in May 2017.
== Biotechnology == The 7kDa proteins are valuable tools in biotechnology due to their ability to bind any dsDNA. When grafted onto a DNA polymerase, it greatly enhances the processivity of the enzyme by helping it stay bound to the DNA. Using such a modified enzyme allows a polymerase chain reaction to copy much longer pieces of DNA at a faster rate. Such fusion polymerases are sold under various tradenames under premium prices since 2014, but they can also be made and purified in a lab. (The commercial versions include additional mutations for performance.) The 7kDa protein scaffold is also a good starting point for artificial affinity proteins (affitins) that can be used to bind any molecule of interest. Techniques such as phage display are used to screen a wide variety of mutants and select for the good binders. Compared to antibodies, they are much smaller and much stabler.
Sources: en.wikipedia.org
isomers Ions or molecules with identical chemical formulas but distinct structures or spatial arrangements. Isomers do not necessarily share similar properties. The two main types of isomers are structural isomers and stereoisomers.
== Structure == Although no crystallographic x-ray diffraction analyses have been published that depict the entire structure of ADAM10, one domain has been studied using this technique. The disintegrin and cysteine-rich domain (shown to the right) plays an essential role in regulation of protease activity in vivo. Recent experimental evidence suggests that this region, which is distinct from the active site, may be responsible for substrate specificity of the enzyme. It is proposed that this domain binds to particular regions of the enzyme's substrate, allowing peptide bond hydrolysis to occur in well defined locations on certain substrate proteins. The proposed active site of ADAM10 has been identified by sequence analysis, and is identical to enzymes in the Snake Venom metalloprotein domain family. The consensus sequence for catalytically active ADAM proteins is HEXGHNLGXXHD. Structural analysis of ADAM17, which has the same active site sequence as ADAM10, suggests that the three histidines in this sequence bind a Zn2+ atom, and that the glutamate is the catalytic residue.
Hard ionization techniques are those that impart high quantities of residual internal energy in the subject molecule, even after ionization. Part of the energy would be dissipated by rupturing chemical bonds within the ion, producing many fragmentary radical cations. The resultant ions tend to have m/z lower than the molecular ion (other than in the case of proton transfer and not including isotope peaks). The most common example of hard ionization is electron ionization (EI). The radical ions produced after the first ionization are called second-generation product ions. The products are then directed towards the mass analyzer by a repeller electrode. The ionization process often follows predictable cleavage reactions that give rise to fragment ions which, following detection and signal processing, convey structural information about the analyte. Conversely, soft ionization techniques are those that impart little residual energy onto the subject molecule and as such result in little fragmentation. Examples include fast atom bombardment (FAB), chemical ionization (CI), atmospheric-pressure chemical ionization (APCI), atmospheric-pressure photoionization (APPI), electrospray ionization (ESI), desorption electrospray ionization (DESI), and matrix-assisted laser desorption/ionization (MALDI).
The Double Qaim-Maqamate of Mount Lebanon (1843–1861) was one of the Ottoman Empire's subdivisions following the abolishment of the Mount Lebanon Emirate. After 1843, there existed an autonomous Mount Lebanon with a Christian and a Druze subdivision, which have been created as a homeland for the Maronite Christians under European diplomatic pressure following the 1841 massacres, and for the Druze segment of the population. After the collapse of the Double Qaim-Maqamate due to the 1860 conflict, the Maronite Catholics and the Druze further developed the idea of an independent Lebanon in the mid-nineteenth century, through the creation of the Mount Lebanon Mutasarrifate. The idea of dividing Mount Lebanon between Christians and Druze was a system proposed by the Austrian Chancellor Metternich between the British and the Ottomans, who backed the Druze demand for a Druze governor, and the French, who insisted on the return of the Shihab principality. Thus, the Druze emir Ahmad Arslan was appointed qāʾim maqām of the mixed southern district and Christian emir Haydar Ahmad Abu al-Lamaʿ qāʾim maqām of the mostly Christian northern district, each qāʾim maqām was to be accompanied by two wakils, a Druze and a Christian, who exercised their judicial and fiscal authority over the members of their respective communities. Emir Haydar Ahmad Abu al-Lamaʿwas a member of Abu'l-Lama clan, which converted to Christianity and joined the Maronite Church at the beginning of the eighteenth century.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.